Welcome to our dedicated page for Natera SEC filings (Ticker: NTRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing Natera鈥檚 genomic jargon isn鈥檛 easy. Each 10-K details everything from cfDNA assay accuracy to payer reimbursement disputes, while 8-K updates often cover fast-moving clinical-trial milestones. If you鈥檝e ever wondered how to locate test-volume data, or needed Natera insider trading Form 4 transactions before the market reacts, you know the challenge.
Stock Titan solves it. Our AI reads every Natera quarterly earnings report 10-Q filing, highlights revenue per test, and translates accounting footnotes into plain language. AG真人官方-time alerts flag Natera Form 4 insider transactions real-time, so you can track executive stock moves the moment they hit EDGAR. Need the full picture? We link each 10-K, 10-Q, 8-K, proxy DEF 14A, and S-8 in one place鈥�Natera SEC filings explained simply. Common questions such as 鈥淗ow do I find the latest Natera proxy statement executive compensation?鈥� or 鈥淲here is the Natera 8-K material events explained?鈥� are answered inside every filing card.
Our platform doesn鈥檛 stop at document delivery. AI-powered summaries spotlight what matters for a diagnostics company: R&D spend versus cash on hand, progress of the Signatera oncology pipeline, and changes in CMS reimbursement that can swing margins. Use cases include:
- Compare quarter-over-quarter test volumes without sifting through tables
- Monitor Natera executive stock transactions Form 4 for buying or selling trends
- Assess dilution risk by reviewing shelf registrations and ATM offerings
- Download an Natera annual report 10-K simplified PDF automatically annotated by AI
- Receive instant alerts when a new Natera earnings report filing analysis is available
- Get guidance on understanding Natera SEC documents with AI-generated glossaries
Whether you鈥檙e a healthcare analyst, portfolio manager, or clinician-investor, Stock Titan turns Natera鈥檚 dense disclosures into actionable insight鈥攏o genetics PhD required.
Moshkevich Solomon, President, Clinical Diagnostics at Natera, Inc. (NTRA), reported equity transactions relating to previously granted restricted stock units. On 08/12/2025, 1,675 RSUs vested after certification of milestone achievement; each RSU converts into one share. Following vesting the reporting person beneficially owned 124,734 shares. On 08/14/2025 the reporting person sold 867 shares at $155.46 and 8 shares at $155.4248 to satisfy tax withholding obligations under a written instruction intended to meet Rule 10b5-1 affirmative defense, leaving 123,859 shares beneficially owned. The Form 4 is signed by an attorney-in-fact on 08/15/2025.
Insider stock vesting and related sales at Natera, Inc. (NTRA). The reporting person had 1,675 restricted stock units (RSUs) vest upon certification that specific time- and performance-based milestones were met; each RSU converts into one share of common stock. Following vesting, the reporting person beneficially owned 153,425 shares before share disposals. To satisfy tax withholding obligations tied to the vesting, the filer sold 678 shares in two transactions at prices of $155.46 and $155.30, leaving 152,747 shares beneficially owned after the reported activity. The sales were made pursuant to a written instruction intended to meet the affirmative defense conditions of Rule 10b5-1.
In this Form 4, Natera director and co-founder Sheena Jonathan reported sales totaling 6,070 shares of Natera common stock: 3,070 shares on 08/08/2025 and 3,000 shares on 08/11/2025. The filing lists weighted-average prices for the 08/08 sales roughly in the mid-$156 to mid-$164 range and for the 08/11 sales roughly in the low-$150 to mid-$156 range. Footnotes state the 08/08 sales were executed under a Rule 10b5-1 plan adopted December 11, 2024, and the 08/11 sales were executed under a separate Rule 10b5-1 plan adopted June 7, 2024.
Following these transactions the reporting person retained 242,252 shares reported as directly owned and reported indirect trust holdings associated with Caraluna trusts in the ~34,282鈥�35,662 share range across the trust entries. No derivative securities were reported.
Insider Form 4 filing 鈥� Natera, Inc. (NTRA)
On 08/01/2025, Solomon Moshkevich (President, Clinical Diagnostics; officer) reported three sales of Natera common stock effected pursuant to a Rule 10b5-1 trading plan adopted on 11/26/2024. The reported dispositions were 1,574 shares at a weighted-average price of $132.4528 (range $131.9350鈥�$132.78), 1,326 shares at $133.3097 (range $132.96鈥�$133.80), and 100 shares at $134.08.
Post-transaction beneficial ownership: reported as 124,485; 123,159; and 123,059 shares respectively. The Form was signed by an attorney-in-fact on 08/05/2025.
Natera, Inc. (NTRA) filed a Form 144 indicating that insider Gail Marcus intends to sell up to 2,496 common shares through Merrill Lynch on or after 1 Aug 2025. The proposed sale is valued at $332,394.72, based on the market price at the time of filing. Natera has 136.55 million shares outstanding, so the planned sale equals <0.01 % of the float.
The shares were acquired via equity-compensation grants on 9 Jun 2024 (2,374 sh) and 26 Jul 2024 (122 sh). Marcus has already sold 12,299 shares over the past three months, generating gross proceeds of 鈮�$1.98 million (4,000 sh on 1 May 2025, 4,000 sh on 10 Jun 2025, 4,299 sh on 1 Jul 2025).
While the filing signals continued insider selling, the absolute volume remains immaterial relative to total shares and does not, by itself, imply a change in the company鈥檚 fundamentals.
FAQ
What is the current stock price of Natera (NTRA)?
What is the market cap of Natera (NTRA)?
